Course treatment with IFN-α2b immobilized on polyethylene glycol stimulates phagocytic activity of peritoneal macrophages and neutrophils, enhances humoral immune response in CBA/CaLac mice, stimulates IL-4 synthesis, and suppresses IFN-γ production by mitogenstimulated splenocytes from experimental animals.
The development of optimal experimental therapeutic schemes of immobilized interferon α-2b (production of JSC «Siberian Center for Pharmacology and Biotechnology», Novosibirsk) administration was conducted in the frame of the common program of pre-clinical study. The drug being studied was administered intragastrically for 3, 5 and 7 days in the therapeutic dose (1.8 × 105 IU/kg). Experimental evaluation of immunotropic properties of immobilized interferon α-2b was carried out at in vivoexperiments in outbred CD1 male mice with using of following tests: the study of drug effect on the phagocytic activity of peritoneal leukocytes (the relative number of phagocytes and the number of bacteria which were assimilated by phagocytes were assessed); the study of drug effect on the humoral immune response (the total number of splenocytes, the relative and absolute number of antibody-forming cells and their functional activity were determined); estimation of drug effect on the cellular immune response with the using of delayed-type hypersensitivity test induced by sheep red blood cells. Based on these data we concluded that course administration of immobilized interferon α-2b in the therapeutic dose for 5 days increased phagocytosis of neutrophils and humoral immune response most effectively. Cell-mediated immune response was significantly increased after 7-fold administration of studied drug.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.